A research team comprising Associate Professor FUNAKOSHI Yohei, Associate Professor YAKUSHIJIN Kimikazu, Professor MINAMI ...
PD-1 Blockade Triggers HBV-Specific B-Cell Responses to Unlock New Combination Immunotherapy Directions for HBV-Associated Hepatocellular Carcinoma July 2026 saw the online publication of high-impact ...
Roche is paying oncology-focused Simcere Zaiming $75 million upfront for global rights to a preclinical trispecific antibody targeting B-cell-mediated diseases. | Roche is paying oncology-focused ...
SAVANNAH, Georgia — Inebilizumab, a first-in-class anti-CD19 B-cell depleting agent, demonstrated both safety and superior efficacy compared with placebo in patients with seropositive generalized ...
Single B-cell technologies have emerged as powerful screening tools to accelerate antibody discovery, offering R&D teams the potential to interrogate millions of individual antibody-secreting cells to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results